SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-056269
Filing Date
2024-05-09
Accepted
2024-05-09 07:12:01
Documents
64
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q amlx-20240331.htm   iXBRL 10-Q 1994694
2 EX-10.1 amlx-ex10_1.htm EX-10.1 33279
3 EX-31.1 amlx-ex31_1.htm EX-31.1 15400
4 EX-31.2 amlx-ex31_2.htm EX-31.2 15392
5 EX-31.3 amlx-ex31_3.htm EX-31.3 15392
6 EX-32.1 amlx-ex32_1.htm EX-32.1 8235
7 EX-32.2 amlx-ex32_2.htm EX-32.2 8233
8 EX-32.3 amlx-ex32_3.htm EX-32.3 8232
  Complete submission text file 0000950170-24-056269.txt   6962010

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT amlx-20240331.xsd EX-101.SCH 911861
67 EXTRACTED XBRL INSTANCE DOCUMENT amlx-20240331_htm.xml XML 1049559
Mailing Address 43 THORNDIKE STREET CAMBRIDGE MA 02141
Business Address 43 THORNDIKE STREET CAMBRIDGE MA 02141 617-683-0917
Amylyx Pharmaceuticals, Inc. (Filer) CIK: 0001658551 (see all company filings)

IRS No.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41199 | Film No.: 24928537
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)